SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts is currently a major focus for investors navigating sector-wide volatility, with the community actively debating the company's valuation against its long-term growth prospects in both brick-and-mortar and digital gaming. Market participants are closely watching the balance between regional casino performance, international expansion opportunities, and the competitive pressures from emerging prediction market platforms that are shifting traditional betting behaviors.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors react to a strong quarterly earnings report and upward-revised fiscal guidance, with the company highlighting record data center demand fueled by AI infrastructure expansion. The community is actively discussing the stock's potential for a breakout, driven by analyst upgrades and momentum in custom silicon and optical interconnect technologies.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors react to activist investor Nelson Peltz signaling that the stock is significantly undervalued, sparking intense speculation regarding a potential buyout or privatization. The community is actively debating the stock's future, weighing the merits of the company's dividend yield and turnaround strategy against frustration over the delayed search for a new CEO.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amidst intense community debate over recent escalations in Iran, with investors and social media users fiercely divided over the administration's foreign policy, the impact on global energy markets, and the company's broader political associations. The community is actively parsing conflicting signals regarding potential peace negotiations and the financial health of the platform, fueling a high-volume discussion that mirrors the polarized nature of the current political environment.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community reacts to the launch of its Super App, with bullish investors highlighting its potential to redefine payroll infrastructure and drive institutional adoption alongside key ecosystem partnerships. While some users are focused on accumulating during volatility, others are debating the project's long-term utility versus market skepticism following recent token unlocks.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is drawing significant attention as investors react to ongoing lobbying efforts by prominent figures like Bill Ackman, who are pushing for the government to divest its stake in the mortgage finance firms. The community is sharply divided between those viewing the recent price action as a strategic buying opportunity for a long-term 'conservatorship exit' play and those skeptical of the timeline given the political complexity and lack of official milestones.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as the stock continues to attract value-focused investors following a strong earnings beat and raised full-year guidance. The community is actively discussing the company's growth portfolio, specifically the performance of Opdivo and Reblozyl, as investors weigh these gains against ongoing generic competition and patent cliff concerns.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is capturing intense market attention as traders react to significant institutional investments from firms like Point72 and ongoing aggressive open-market buying by the CEO. The community is focused on the potential for a strategic partnership or buyout, viewing the firm's late-stage clinical data as a catalyst for a possible short squeeze given the relatively limited tradable float.

Woodside Energy Group Ltd. engages in the exploration, evaluation, development, and production of hydrocarbon and oil and gas properties. It operates through the following segments: North West Shelf, Pluto, Australia Oil, Wheatstone, Development, and Others. The North West Shelf segment produces liquefied natural gas, pipeline natural gas, condensate, liquefied petroleum gas and crude oil from the North West Shelf ventures. The Pluto segment develops liquefied natural gas in assigned permit areas. The Australia Oil segment is involved in the exploration, evaluation, development, production and sale of crude oil in assigned permit areas. The Wheatstone segment is involved in the exploration, evaluation, and development of liquefied natural gas, pipeline natural gas, and condensate. The Development segment includes the exploration of gas resources in Scarborough, Sangomar, and other project areas. The Other segment is composed of the activities undertaken by exploration, international and Sunrise Business Units. The company was founded on July 26, 1954 and is headquartered in Perth, Australia.

Woodside Energy Group Ltd - ADR

Woodside Energy is trending as investors monitor ongoing disruptions in the global LNG market, specifically concerns surrounding key transit chokepoints and the ripple effects on international supply chains. Community sentiment is largely focused on the company's strategic positioning to capture higher pricing amid these supply shortages, while some discussions center on the risks and opportunities associated with potential new infrastructure and capacity expansion projects.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is under increased scrutiny as reports emerge of the company planning a major reduction in shipment volumes through the U.S. Postal Service to lower costs, while simultaneously expanding its ultra-fast delivery offerings in hundreds of U.S. cities. Meanwhile, the stock is seeing significant institutional attention, with traders closely monitoring the impact of increased AI infrastructure spending and potential legal challenges surrounding cloud deals involving OpenAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Humacyte (HUMA) Projected to Post Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA) will be releasing its Q4 2025 earnings before the market opens on Friday, March 27. (View Earnings Report at...

<ul class="summary-bullets"><li>Humacyte is looking to sell 25 million shares in order to raise $20 million.</li><li>The company said it plans to use the proceeds to support the commercialization of Symvess for vascular trauma.</li><li>Humacyte also agreed not to pursue other commercialization negotiations in Saudi Arabia until July 2026.</li></ul>Shares of Humacyte, Inc. (HUMA) tanked more than 20% to an all-time low on Thursday, after the company announced a $20 million fundraising at a significant discount to the stock’s closing price a day earlier.Simultaneously, the company also announced a $1.5 million minimum purchase commitment from Saudi Arabia for its&nbsp;Symvess, a bioengineered, off-the-shelf human blood vessel.Humacyte signed a new securities purchase agreement with several new institutional investors to sell 25 million shares of common stock in a registered direct offering. The deal is expected to generate gross proceeds of about $20 million and is slated to close around March 20, 2026. This translates to $0.80 per share, a 25% discount to the stock’s Wednesday closing price of $1.06.The company added that it plans to use the proceeds to support the commercialization of Symvess for vascular trauma, advance a Biologics License Application (BLA) supplement for hemodialysis use, and fund ongoing clinical and pipeline development programs.<h2 class="st-heading-2">Humacyte Is In Talks To Form JV In Saudi Arabia</h2>Humacyte said the order will support a clinical evaluation and outreach program in hospitals across Saudi Arabia. The company is also in talks to form a joint venture and secure commercialization rights for Symvess in the country.Humacyte will train local medical professionals to use the product and has agreed not to pursue any other commercialization negotiations in Saudi Arabia until July 2026. While Symvess is FDA-approved for the treatment of extremity vascular trauma, other uses remain investigational.“The clinical evaluation and outreach program is designed to build awareness and understanding of the Symvess technology among healthcare providers as we pursue regulatory approval and prepare for potential commercial launch in the KSA,” said Laura Niklason, Founder and CEO of Humacyte.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.One user believes <a href="https://stocktwits.com/symbol/HUMA">HUMA</a> is a “great candidate” for a reverse stock split.<stembedurl>https://stocktwits.com/Morslan/message/647964164</stembedurl>Another user expects the stock to fall to $0.3. It is currently trading around $0.8.<stembedurl>https://stocktwits.com/paulN98/message/647972889</stembedurl>Year-to-date, the stock has declined around 10%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rivn-stock-jump-in-pre-market-today/cZ3aSSTRIhb">Uber Expands Autonomous Vehicle Push - Here’s Everything To Know About Its Partnership With Rivian</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stocks chart. (Image Courtesy: Getty Images)

Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?

The company said it is in talks to form a joint venture and secure commercialization rights for Symvess, a bioengineered blood vessel, in Saudi Arabia.

Equity

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday...

Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional...

D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reissued a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a report on Thursday...

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One...

Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.

Humacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Monday...

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Current Price	$0.7829
Prev Close	$0.8541
Open	$0.9027
Dividend Yield	0.00%
50-Day Moving Average	$1.08
Beta	2.04
Avg. Volume	6.22M
PE Ratio	-3.28

52-Week High	$3.36
52-Week Low	$0.701
Market Capitalization	$151.1M
EPS (Annual)	-$1.26
Price to Book	-26.18
Revenue Per Employee	$0.00

HUMA
Humacyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HUMA News

HUMAHumacyte Inc